Aurinia lupus candidate hits PhII target, but deaths send stock down - FierceBiotech

FierceBiotech

Aurinia lupus candidate hits PhII target, but deaths send stock down FierceBiotech Aurinia Pharmaceuticals has published positive new data for its experimental drug voclosporin for active lupus nephritis--but 12 deaths in the study's treatment arm has sent alarm bells ringing. Canadian biotech Aurinia Pharmaceuticals ($AUPH) posted ... Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus ...Business Wire (press release) Leerink Partners Reiterates 'Outperform' on Aurinia Pharmaceuticals (AUPH) Following Phase 2b AURA-LV ResultsStreetInsider.com Why Aurinia Pharma Is Getting Slaughtered24/7 Wall St. Seeking Alpha -Economic Calendar all 8 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNE8RxhVYJo8XDDefKJLdSfojA0HPg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779182246896&ei=UdyxV4j3D4XJ3gGUmaHQBg&url=http://www.fiercebiotech.com/biotech/aurinia-pharmaceuticals-lupus-candidate-aces-phii-prepares-for-fda-talks
via IFTTT